NETRIS Pharma Announces Clinical Trial Collaboration Agreement with MSD to Evaluate NP137 in Combination with KEYTRUDA® (Pembrolizumab) in Advanced Uterine and Cervical Tumors Unique NP137 mechanism targeting netrin-1 could alleviate…
NETRIS Pharma is pleased to announce that the ANR (Agence Nationale de la Recherche) allocated a 6.6 M€ grant to the RHU DEPGYN project aiming to develop new therapeutic approaches…
NETRIS Pharma will attend the Colloque on Women Cancer in Paris (March 30th, 2019). In partnership with “La Ligue contre le Cancer” Association, the following theme will be discussed by…
NETRIS Pharma will attend the 37th Annual J.P. Morgan Healthcare Conference in San Francisco, California (January 07th-10th, 2019). Our team members attending the event will be pleased to meet you for…
NETRIS Pharma successfully completes first clinical study with first-in-class netrin-1 inhibitor NP137 in patients with advanced solid tumors Dose-escalation part of study met primary objective Study shows NP137 to have…
NETRIS Pharma will attend the 2018 BIO International Convention event in Boston, MA (June 04th-07th). Our team members attending the event will be pleased to meet you for discussing opportunities…
NETRIS Pharma will attend PEGS 2018 event in Boston, MA (April 30th-May 04th). Our CEO, Pr. Patrick Mehlen, will give a presentation on April 30th within the Oncology stream – Antibodies…
NETRIS Pharma will attend the BIO-Europe Spring 2018 event in Amsterdam, Netherlands (March 12th-14th). Our team members attending the event will be pleased to meet you for discussing opportunities with…
The President of the French Republic appointed Pr. Agnès Bernet, co-founder and CSO of NETRIS Pharma, to the highest French distinction as Knight of the Legion of Honor. The award…
NETRIS Pharma will attend the 36th Annual J.P. Morgan Healthcare Conference in San Francisco, California (January 08th-11th, 2018). Our team members attending the event will be pleased to meet you…
NETRIS Pharma will attend the BIO-Europe 2017 meeting in Berlin, Germany (November 06th-08th). Our team members attending the event will be pleased to meet you for discussing opportunities with potential…
Lyon, France – 21 March 2017 – NETRIS Pharma Starts Enrollment of First Clinical Study to Evaluate Drug Candidate Targeting Dependence Receptors. NETRIS Pharma, a pioneer in the development of dependence…
NETRIS Pharma announces the approval of Agence Nationale de Sécurité des Médicaments et produits de santé (ANSM) for the clinical evaluation of NP137, its first humanized monoclonal antibody targeting Netrin-1….
NETRIS Pharma announces that ANR (Agence Nationale de la Recherche) granted the translational RHU TROY program aiming at Targeting dependence Receptors (DRs) in Oncology and hematologY. This program aims at…
NETRIS Pharma announces that Agnès Bernet – co-founder and CSO of NETRIS Pharma – received the 2015 Irène Joliot-Curie award from the French Minister of Education and Research and the…
NETRIS Pharma will attend the BioEquity Europe 2015 meeting in Vienna, Austria (May 19th-20th). During the “Next Wave Companies” session, Stéphane Depil – CEO – will present NETRIS Pharma activities…
NETRIS Pharma will attend the AACR Annual Meeting 2015 in Philadelphia, US (April 18th-22nd). For this occasion, NETRIS Pharma will present recent data regarding its first-in-class humanized anti-Netrin-1 antibody NP137,…
